416 related articles for article (PubMed ID: 32416330)
21. Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome.
Chen LYC; Hoiland RL; Stukas S; Wellington CL; Sekhon MS
Eur Respir J; 2020 Oct; 56(4):. PubMed ID: 32883678
[TBL] [Abstract][Full Text] [Related]
22. Outcomes in patients with severe COVID-19 disease treated with tocilizumab: a case-controlled study.
Rojas-Marte G; Khalid M; Mukhtar O; Hashmi AT; Waheed MA; Ehrlich S; Aslam A; Siddiqui S; Agarwal C; Malyshev Y; Henriquez-Felipe C; Sharma D; Sharma S; Chukwuka N; Rodriguez DC; Alliu S; Le J; Shani J
QJM; 2020 Aug; 113(8):546-550. PubMed ID: 32569363
[TBL] [Abstract][Full Text] [Related]
23. Clinical exacerbation of SARS-CoV2 infection after fingolimod withdrawal.
Gomez-Mayordomo V; Montero-Escribano P; Matías-Guiu JA; González-García N; Porta-Etessam J; Matías-Guiu J
J Med Virol; 2021 Jan; 93(1):546-549. PubMed ID: 32644205
[TBL] [Abstract][Full Text] [Related]
24. Predictive factors of mortality in patients treated with tocilizumab for acute respiratory distress syndrome related to coronavirus disease 2019 (COVID-19).
Lohse A; Klopfenstein T; Balblanc JC; Royer PY; Bossert M; Gendrin V; Charpentier A; Bozgan AM; Badie J; Bourgoin C; Contreras R; Mazurier I; Conrozier T; Zayet S
Microbes Infect; 2020 Oct; 22(9):500-503. PubMed ID: 32574789
[TBL] [Abstract][Full Text] [Related]
25. Clinicolaboratory study of 25 fatal cases of COVID-19 in Wuhan.
Tu WJ; Cao J; Yu L; Hu X; Liu Q
Intensive Care Med; 2020 Jun; 46(6):1117-1120. PubMed ID: 32253448
[No Abstract] [Full Text] [Related]
26. Audio Interview: Tocilizumab and Covid-19.
Rubin EJ; Baden LR; Morrissey S
N Engl J Med; 2020 Oct; 383(17):e114. PubMed ID: 33085870
[No Abstract] [Full Text] [Related]
27. Interleukin-6 blockade treatment for COVID-19 associated cytokine release syndrome in a patient with poorly controlled chronic myeloid leukaemia.
Ranger A; Haji R; Kaczmarski R; Danga A
Br J Haematol; 2020 Aug; 190(3):e128-e130. PubMed ID: 32480422
[No Abstract] [Full Text] [Related]
28. Vascular microthrombosis associated with increased interleukin-6. A severe acute respiratory distress syndrome in COVID-19 patients treated with tocilizumab.
Mohebbi N; Abedini A; Lashgari R; Razavi F; Varahram M; Kiani A
Adv Respir Med; 2020; 88(5):468-469. PubMed ID: 33169824
[No Abstract] [Full Text] [Related]
29. Outcome of COVID-19 patients with use of Tocilizumab: A single center experience.
Zain Mushtaq M; Bin Zafar Mahmood S; Jamil B; Aziz A; Ali SA
Int Immunopharmacol; 2020 Nov; 88():106926. PubMed ID: 32889236
[TBL] [Abstract][Full Text] [Related]
30. COVID-19 in patients with myasthenia gravis.
Anand P; Slama MCC; Kaku M; Ong C; Cervantes-Arslanian AM; Zhou L; David WS; Guidon AC
Muscle Nerve; 2020 Aug; 62(2):254-258. PubMed ID: 32392389
[TBL] [Abstract][Full Text] [Related]
31. The multiple sclerosis (MS) drugs as a potential treatment of ARDS in COVID-19 patients.
Kloc M; Ghobrial RM
Mult Scler Relat Disord; 2020 Oct; 45():102437. PubMed ID: 32763844
[TBL] [Abstract][Full Text] [Related]
32. Vitamin D: A simpler alternative to tocilizumab for trial in COVID-19?
Silberstein M
Med Hypotheses; 2020 Jul; 140():109767. PubMed ID: 32353742
[TBL] [Abstract][Full Text] [Related]
33. Kidney Transplantation and COVID-19.
Merhi B; Gohh R
R I Med J (2013); 2020 Sep; 103(8):34-37. PubMed ID: 32900010
[No Abstract] [Full Text] [Related]
34. Amelioration of COVID-19-related cytokine storm syndrome: parallels to chimeric antigen receptor-T cell cytokine release syndrome.
Hoiland RL; Stukas S; Cooper J; Thiara S; Chen LYC; Biggs CM; Hay K; Lee AYY; Shojania K; Abdulla A; Wellington CL; Sekhon MS
Br J Haematol; 2020 Aug; 190(3):e150-e154. PubMed ID: 32584416
[No Abstract] [Full Text] [Related]
35. Impact of coronavirus disease (COVID-19) pandemic on multiple sclerosis care.
Salama S; Ahmed SF; Ibrahim Ismail I; Alroughani R
Clin Neurol Neurosurg; 2020 Oct; 197():106203. PubMed ID: 32919242
[No Abstract] [Full Text] [Related]
36. Tocilizumab plus glucocorticoids in severe and critically COVID-19 patients. A single center experience.
Jiménez-Brítez G; Ruiz P; Soler X
Med Clin (Barc); 2020 Nov; 155(9):410-411. PubMed ID: 32718713
[No Abstract] [Full Text] [Related]
37. How does COVID-19 kill? Uncertainty is hampering doctors' ability to choose treatments.
Ledford H
Nature; 2020 Apr; 580(7803):311-312. PubMed ID: 32273618
[No Abstract] [Full Text] [Related]
38. COVID-19 infection in a patient with multiple sclerosis treated with fingolimod.
Barzegar M; Mirmosayyeb O; Nehzat N; Sarrafi R; Khorvash F; Maghzi AH; Shaygannejad V
Neurol Neuroimmunol Neuroinflamm; 2020 Jul; 7(4):. PubMed ID: 32371550
[No Abstract] [Full Text] [Related]
39. Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab.
Morrison AR; Johnson JM; Griebe KM; Jones MC; Stine JJ; Hencken LN; To L; Bianchini ML; Vahia AT; Swiderek J; Ramesh MS; Peters MA; Smith ZR
J Autoimmun; 2020 Nov; 114():102512. PubMed ID: 32646770
[TBL] [Abstract][Full Text] [Related]
40. Immune checkpoint inhibitors: a physiology-driven approach to the treatment of coronavirus disease 2019.
Di Cosimo S; Malfettone A; Pérez-García JM; Llombart-Cussac A; Miceli R; Curigliano G; Cortés J
Eur J Cancer; 2020 Aug; 135():62-65. PubMed ID: 32544799
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]